

ASX RELEASE

ASX Code: ESE



ORIGINATING MOTION PROCEEDING AGAINST DR BRENDAN DE KAUWE

On March 21, 2018, life sciences company **eSense-Lab Ltd** ("**eSense**" or the "**Company**") (**ASX: ESE**) commenced an originating motion proceeding in the Central District Court in Lod, Israel (the "**Court**") against one of the members of the Company's Board of Directors, Dr Brendan de Kauwe.

In the context of the proceedings, the Company requested that the Court instruct Dr de Kauwe to comply with the resolution of the Board of Directors of January 19, 2018, regarding the change in the Company's signature rights regarding the Company's account at National Australia Bank ("**NAB**"), which prevents the funding of the Company's ongoing operations in accordance with its approved budget and ongoing needs.

The Company also requested, as a temporary remedy, that the Court instruct Dr de Kauwe to comply with the resolutions of the Board of Directors regarding the approval of the Company's budget for the 2018 fiscal year by signing the documents required by NAB, such that the Company will be able to transfer funds from its Australian bank account in accordance with the Company's budget for the period until the delivery of the Court's ruling in the originating motion.

On March 21, 2018, the Court ruled that Dr de Kauwe's response to the Company's request for temporary remedies should be filed with the Court by March 28, 2018, at 13:00 Israel time

FOR FURTHER INFORMATION:

Company Secretary

Ian Pamensky
+61 414 864 746
ian@cfo2grow.com.au

Investor/media relations

Matthew Wright
+61 451 896 420
matt@nwrcommunications.com.au

About eSense-Lab

eSense-Lab Ltd (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense-Lab can then use this model to 'reverse engineer' a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant's health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost

To learn more about eSense-Lab, visit www.esense-lab.com